AM Pharma is a brand that is dedicated to saving and improving the lives of patients with severe medical conditions. Their primary focus is on acute kidney injury (AKI), a condition that affects hundreds of thousands of people annually. Their proprietary compound, ilofotase alfa, has shown great potential in becoming the first treatment for AKI, with positive effects demonstrated in almost 1,000 patients through global clinical trials.

AM Pharma is driven by a dedicated team that is committed to bringing treatment options to severely ill patients, their families, and specialty care professionals. In addition to developing a treatment for AKI, the company is also focused on using their expertise to address other severe medical conditions, including orphan indications. Their mission is to develop medicines for patients facing such conditions.

The brand prides itself on its core values of collaboration, quality orientation, accountability, and resilience. They work together as a team, prioritizing the common interest of patients and the company. They maintain high standards when it comes to the quality of their work and are accountable for their actions.

They remain resilient in the face of challenges and setbacks, staying committed to their goals and adjusting plans when necessary. With a strong management team, including individuals with extensive experience in the pharmaceutical industry, AM Pharma is well-positioned to continue their mission of improving patient outcomes and providing much-needed treatment options